Antimicrobial resistance as an externality of antibiotic consumption: Correlations and implications for the pharmacoeconomic evaluation of antibiotic use in hospital settings;Antimikrobielle resistenz als externer effekt des einsatzes von antibiotika - Zusammenhänge und implikationen für die pharmakoökonomische analyse des klinikinternen einsatzes von antibiotika

Gesundheitsokonomie und Qualitatsmanagement

Volumn 14, Issue 3, 2009, Pages 127-131

  Kaiser, Klaus ^a,b   Frank, U ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Antimicrobial resistance; Costs; Economic model; Externality

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG COST; DRUG USE; HEALTH INSURANCE; HOSPITALIZATION COST; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION;

EID: 67649622692     PISSN: 14322625     EISSN: 14394049     Source Type: Journal    
DOI: 10.1055/s-2008-1027791     Document Type: Article

References (32)

1. Greiner W, Rasch A, Kohler D et al. Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients. Clin Microbiol Infect 2007; 13: 264-268 (Pubitemid 46603356)
2. Jansen WTM, van der Bruggen JT, Verhoef J et al. Bacterial resistance: A sensitive issue - Complexity of the challenge and containment strategy in Europe. Drug Resist Updat 2006; 9: 123-133 (Pubitemid 44279521)
3. Kipp F, Friedrich AW, Becker K et al. Bedrohliche Zunahme Methicillin-resistenter Staphylococcus-aureus-Stämme. Dtsch Arztebl 2004; 101: A2045-A2050
4. Wernitz MH, Keck S, Swidsinski S et al. Cost analysis of a hospital-wide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers in the context of diagnosis related groups (DRG) payment. Clin Microbiol Infect 2005; 11: 466-471 (Pubitemid 40744393)
5. Cosgrove SE, Qi Y, Kaye KS et al. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26: 166-174 (Pubitemid 40445022)
6. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: Mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006; 42: S82-S89 (Pubitemid 43054219)
7. Geldner G, Ruoff M, Hoffmann H-J et al. Eine Kostenanalyse von MRSAInfektionen auf einer operativen Intensivstation. Anästhesiol Intensivmed Notfallmed Schmerzther 1999; 34: 409-413 (Pubitemid 29356673)
8. Kreutzer J, Nußbaum B, Bernd L et al. Reale Kosten der MRSA-Osteitis. Trauma Berufskrankh 2002; 4: 344-349
9. Rubin RJ, Harrington CA, Poon A et al. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis 1999; 5: 9-17 (Pubitemid 29124770)
10. Shorr AF. Epidemiology and economic impact of meticillin-resistant Staphylococcus aureus: review and analysis of the literature. Pharmacoeconomics 2007; 25: 751-768 (Pubitemid 47481640)
11. Cranny G, Elliott R, Weatherly H et al. A systematic review and economic model of switching from non-glycopeptide to glycopeptide antibiotic prophylaxis for surgery. Health Technol Assess 2008; 12: 1-147 (Pubitemid 351200903)
12. Ruef C. Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus. Infection 2004; 32: 315-327 (Pubitemid 40104674)
13. Schürmann D, Sorensen SV, De CE et al. Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany. Eur J Health Econ Epub 24 April 2008 10.1007/s10198 - 008 - 0104-107
14. Aldeyab MA, Monnet DL, Lopez-Lozano JM et al. Modelling the impact of antibiotic use and infection control practices on the incidence of hospital-acquired methicillin-resistant Staphylococcus aureus: a time- series analysis. J Antimicrob Chemother Epub 7 May 2008 10.1093/jac/dkn198
15. Crowcroft NS, Ronveaux O, Monnet DL et al. Methicillin-resistant Staphylococcus aureus and antimicrobial use in Belgian hospitals. Infect Control Hosp Epidemiol 1999; 20: 31-36
16. Kaier K, Hagist C, Frank U et al. Antimicrobial drug use, alcohol-based hand disinfection and the burden of methicillin-resistant Staphylococcus aureus - A time series approach at a German University Medical Center. Discussion Paper of the Research Center for Generational Contracts 2008; 27
17. MacDougall C, Powell JP, Johnson CK et al. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 2005; 41: 435-440 (Pubitemid 41099634)
18. Monnet DL, MacKenzie FM, Lopez-Lozano JM et al. Antimicrobial drug use and methicillin-resistant Staphylococcus aureus. Aberdeen 1996-2000. Emerg Infect Dis 2004; 10: 1432-1441
19. Vernaz N, Sax H, Pittet D et al. Temporal effects of antibiotic use and hand rub consumption on the incidence of MRSA and Clostridium difficile. J Antimicrob Chemother Epub 8 May 2008 10.1093/jac/dkn199
20. Coast J, Smith RD, Millar MR. Superbugs: Should antimicrobial resistance be included as a cost in economic evaluation. Health Econ 1996; 5: 217-226 (Pubitemid 126482627)
21. Coast J, Smith RD, Millar MR. An economic perspective on policy to reduce antimicrobial resistance. Soc Sci Med 1998; 46: 29-38 (Pubitemid 28014365)
22. Elbasha EH. Deadweight loss of bacterial resistance due to overtreatment. Health Econ 2003; 12: 125-138 (Pubitemid 36204169)
23. Phelps CE. Bug/drug resistance. Sometimes less is more. Med Care 1989; 27: 194-203
24. Smith RD, Yago M, Millar M et al. A macroeconomic approach to evaluating policies to contain antimicrobial resistance: A case study of methicillin-resistant Staphylococcus aureus (MRSA). Appl Health Econ Health Policy 2006; 5: 55-65 (Pubitemid 43927200)
25. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 2004; 41: S122-S129 (Pubitemid 40018235)
26. Andersson DI, Levin BR. The biological cost of antibiotic resistance. Curr Opin Microbiol 1999; 2: 489-493 (Pubitemid 29477174)
27. McGowan JE. Economic impact of antimicrobial resistance. Emerg Infect Dis 2001; 7: 286-292 (Pubitemid 32374346)
28. Howard DH. Resistance-induced antibiotic substitution. Health Econ 2004; 13: 585-595 (Pubitemid 38787150)
29. Howard DH, Scott RD. The economic burden of drug resistance. Clin Infect Dis 2005; 41: S283-S286 (Pubitemid 41099626)
30. Wilton P, Smith R, Coast J et al. Strategies to contain the emergence of antimicrobial resistance: a systematic review of effectiveness and cost-effectiveness. J Health Serv Res Policy 2002; 7: 111-117 (Pubitemid 34984017)
31. Greiner W. Die Rolle der Pharmaökonomie zur Ressourcenallokation im Gesundheitswesen - Überblick und Implikationen für Deutschland. Ges ökon Qual manag 2007; 12: 51-56 (Pubitemid 46391331)
32. Kobelt G. Modelle als Instrument der Gesundheitsökonomie. Ges ökon Qual manag 2005; 10 (Suppl 2): S37-S44 (Pubitemid 41290784)